Long-term therapeutic success of intravenous rituximab in 26 patients with indolent primary cutaneous B-cell lymphoma

5Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Systemic monotherapy with rituximab is a well-known treatment approach for primary cutaneous follicle centre lymphoma and primary cutaneous marginal zone lymphoma. Both have excellent prognosis despite high relapse rates. To investigate the long-term effectiveness and clinical outcome of intravenous rituximab at a dose of 375 mg/m2 once weekly, data for 26 patients (17 primary cutaneous follicle centre lymphoma and 9 primary cutaneous marginal zone lymphoma) were analysed retrospectively. Complete remissions occur-red in 20 (77%) and partial remissions in 6 patients (23%), demonstrating an overall response rate of 100%. The relapse rate was 52.9% in primary cutaneous follicle centre lymphoma and 88.9% in primary cutaneous marginal zone lymphoma. Ongoing complete remissions after therapy with rituximab were ob-served in 9 patients (34.6%) with a median progres-sion-free survival of 161 months (13.4 years). These results confirm that intravenous rituximab is an effec-tive and well-tolerated treatment with durable responses in a relevant percentage of patients at a median follow-up of 148 months (12.3 years).

Cite

CITATION STYLE

APA

Porkert, S., Mai, P., Jonak, C., Weihsengruber, F., Rappersberger, K., Bauer, W., … Valencak, J. (2021). Long-term therapeutic success of intravenous rituximab in 26 patients with indolent primary cutaneous B-cell lymphoma. Acta Dermato-Venereologica, 101(2), 1–5. https://doi.org/10.2340/00015555-3746

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free